Physician profile
Xin Li
NPI 1639442429
$1,545.24
in general payments reported to CMS, 2019-2025
26 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $50.11 · 2021: $290 · 2022: $254 · 2023: $102 · 2024: $13.93 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $237.93 | 2019-2025 | Lynparza |
| Amgen INC. | $204.69 | 2019-2022 | |
| Pfizer INC. | $165.72 | 2019-2022 | |
| Daiichi Sankyo INC. | $156.26 | 2019-2025 | Datroway |
| Beigene USA, INC. | $102.32 | 2023 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $80.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $76.79 | 2022 | |
| Exelixis INC. | $73.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.49 | 2019-2024 | |
| Seagen INC. | $54.04 | 2021-2022 | |
| Tesaro, INC. | $40.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $29.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.04 | 2019 | |
| Janssen Biotech, INC. | $24.39 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $21.15 | 2019 | |
| Celgene Corporation | $17.95 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.41 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $16.85 | 2019 | |
| Rigel Pharmaceuticals, INC. | $16.51 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Agios Pharmaceuticals, INC. | $15.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2019 | |
| Abbvie INC. | $14.78 | 2019 | |
| Merck Sharp & Dohme LLC | $13.87 | 2019 | |
| Taiho Oncology, INC. | $13.46 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.